N-(2,3-dihydroxypropyl) carbamoyl side chain : a potentially significant factor for recurrent iodinated contrast medium-related adverse drug reactions
© 2024. The Author(s), under exclusive licence to European Society of Radiology..
PURPOSE: To determine whether switching to contrast media based on the sharing of N-(2,3-dihydroxypropyl) carbamoyl side chain reduces the recurrence of iodinated contrast media (ICM)-associated adverse drug reactions (ADRs).
MATERIALS AND METHODS: This single-center retrospective study included 2133 consecutive patients (mean age ± SD, 56.1 ± 11.4 years; male, 1052 [49.3%]) who had a history of ICM-associated ADRs and underwent contrast-enhanced CT examinations. The per-patient and per-exam-based recurrence ADR rates were compared between cases of switching and non-switching the ICM from ICMs that caused the previous ADRs, and between cases that used ICMs with common and different carbamoyl side chains from ICMs that caused the previous ADRs. Downgrade rates (no recurrence or the occurrence of ADR less severe than index ADRs) were also compared. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) analysis were additionally performed.
RESULTS: In per-patient analysis, switching of ICM showed a lower recurrence rate (switching, 10.4% [100/965] vs. non-switching, 28.4% [332/1168]), with the adjusted odds ratio (OR) of 0.27 (95% CI: 0.21, 0.34; p < 0.001). The result was consistent in PSM (OR, 0.29 [95% CI: 0.22, 0.39]; p < 0.001), IPTW (OR, 0.28 [95% CI: 0.22, 0.36]; p < 0.001), and in per-exam analysis (5.5% vs. 13.8%; OR, 0.32 [95% CI: 0.27, 0.37]; p < 0.001). There was lower per-exam recurrence (5.0% [195/3938] vs. 7.8% [79/1017]; OR, 0.63 [95% CI: 0.47, 0.83]; p = 0.001) and higher downgrade rates (95.6% [3764/3938] vs. 93.3% [949/1017]; OR, 1.51 [95% CI: 1.12, 2.03]; p = 0.006) when using different side chain groups.
CONCLUSION: Switching to an ICM with a different carbamoyl side chain reduced the recurrent ADRs and their severity during subsequent examinations.
CLINICAL RELEVANCE STATEMENT: Switching to an iodinated contrast media with a different carbamoyl side chain reduced the recurrent adverse drug reactions and their severity during subsequent examinations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
European radiology - (2024) vom: 16. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Pyeong Hwa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Contrast media |
|---|
| Anmerkungen: |
Date Revised 19.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s00330-024-10730-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371147166 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371147166 | ||
| 003 | DE-627 | ||
| 005 | 20240419232738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240416s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00330-024-10730-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1380.xml |
| 035 | |a (DE-627)NLM371147166 | ||
| 035 | |a (NLM)38625610 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Pyeong Hwa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a N-(2,3-dihydroxypropyl) carbamoyl side chain |b a potentially significant factor for recurrent iodinated contrast medium-related adverse drug reactions |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to European Society of Radiology. | ||
| 520 | |a PURPOSE: To determine whether switching to contrast media based on the sharing of N-(2,3-dihydroxypropyl) carbamoyl side chain reduces the recurrence of iodinated contrast media (ICM)-associated adverse drug reactions (ADRs) | ||
| 520 | |a MATERIALS AND METHODS: This single-center retrospective study included 2133 consecutive patients (mean age ± SD, 56.1 ± 11.4 years; male, 1052 [49.3%]) who had a history of ICM-associated ADRs and underwent contrast-enhanced CT examinations. The per-patient and per-exam-based recurrence ADR rates were compared between cases of switching and non-switching the ICM from ICMs that caused the previous ADRs, and between cases that used ICMs with common and different carbamoyl side chains from ICMs that caused the previous ADRs. Downgrade rates (no recurrence or the occurrence of ADR less severe than index ADRs) were also compared. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) analysis were additionally performed | ||
| 520 | |a RESULTS: In per-patient analysis, switching of ICM showed a lower recurrence rate (switching, 10.4% [100/965] vs. non-switching, 28.4% [332/1168]), with the adjusted odds ratio (OR) of 0.27 (95% CI: 0.21, 0.34; p < 0.001). The result was consistent in PSM (OR, 0.29 [95% CI: 0.22, 0.39]; p < 0.001), IPTW (OR, 0.28 [95% CI: 0.22, 0.36]; p < 0.001), and in per-exam analysis (5.5% vs. 13.8%; OR, 0.32 [95% CI: 0.27, 0.37]; p < 0.001). There was lower per-exam recurrence (5.0% [195/3938] vs. 7.8% [79/1017]; OR, 0.63 [95% CI: 0.47, 0.83]; p = 0.001) and higher downgrade rates (95.6% [3764/3938] vs. 93.3% [949/1017]; OR, 1.51 [95% CI: 1.12, 2.03]; p = 0.006) when using different side chain groups | ||
| 520 | |a CONCLUSION: Switching to an ICM with a different carbamoyl side chain reduced the recurrent ADRs and their severity during subsequent examinations | ||
| 520 | |a CLINICAL RELEVANCE STATEMENT: Switching to an iodinated contrast media with a different carbamoyl side chain reduced the recurrent adverse drug reactions and their severity during subsequent examinations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Contrast media | |
| 650 | 4 | |a Drug-related side effects and adverse reactions | |
| 650 | 4 | |a Tomography, X-ray computed | |
| 700 | 1 | |a Suh, Chong Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Eun Bee |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seonok |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Kye Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Hyo Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Ah Young |e verfasserin |4 aut | |
| 700 | 1 | |a Do, Kyung-Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jeong Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jin Hyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Ah Young |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Choong Wook |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European radiology |d 1991 |g (2024) vom: 16. Apr. |w (DE-627)NLM087691310 |x 1432-1084 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:16 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00330-024-10730-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 16 |c 04 | ||